MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
MIT researchers discovered a way to treat Fragile X syndrome by targeting NMDA receptors, restoring synaptic balance and ...
A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.
Researchers identified a rare genetic mutation in two schizophrenia patients that increased schizophrenia-related behaviors ...
To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called Glyx-13. This drug binds to the 2B subunit of NMDA receptors to augment ...
AZoLifeSciences on MSN7d
Targeting NMDA Receptor Subunit Shows Promise for Fragile X SyndromeBuilding on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...
To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called Glyx-13. This drug binds to the 2B subunit of NMDA receptors to augment ...
New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback